Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,305.00 +166.84 1.10%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,232.50 +51.73 1.00%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Biogen Idec Inc

+ Add to Watchlist

BIIB:US

226.8500 USD 1.1400 0.50%

As of 20:10:00 ET on 05/17/2013.

Company Profile for Biogen Idec Inc (BIIB)

Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

Contact Information

Biogen Idec Inc

133 Boston Post Rd.
Weston, MA 02493
United States
Phone: 1-781-464-2000
Fax: 1-617-679-2617

Key Executives for Biogen Idec Inc (BIIB)

William D Young "Bill"ChairmanGeorge A ScangosChief Executive Officer
Susan H AlexanderExec VP/Chief Legal Ofcr/SecyPaul J ClancyExec VP:Finance/CFO
Kenneth A DipietroExec VP:Human ResourcesStephen H Holtzman "Steve"Exec VP:Corp Development
Stuart A Kingsley "Tony"Exec VP:Global Commercial OpsJohn G CoxExec VP:Pharmaceutical
Douglas Edward Williams "Doug"Exec VP:Research & DevClaudine ProwseVP:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil